BioSpace News Archive

Vor Bio today announced that it will participate in a fireside chat and host virtual 1x1 investor meetings at the JMP Securities Hematology and Oncology Summit.

Roivant (Nasdaq: ROIV) and Priovant today announced the Phase 2 study evaluating oral brepocitinib in adult patients with moderate to severe active lupus did not meet its primary endpoint of Systemic Lupus Erythematosus Responder Index change of 4 (SRI-4) at Week 52. Priovant plans to disclose the study data at a future date.

New research shows that a short online course designed by global eye care nonprofit Orbis International successfully trains health care workers to identify signs of glaucoma at a level similar to local ophthalmologists.

The second Dupixent® investigational Phase 3 chronic obstructive pulmonary disease trial has shown that Dupixent significantly reduced exacerbations, confirming positive published results from the landmark Phase 3 BOREAS trial.

Regeneron Pharmaceuticals, Inc. and Sanofi announced that the second Dupixent® investigational Phase 3 chronic obstructive pulmonary disease trial showed that Dupixent significantly reduced exacerbations, confirming positive results from the landmark Phase 3 BOREAS trial.

Hemogenyx Pharmaceuticals plc is pleased to announce that its Chimeric Bait Receptor platform can potentially be used in the treatment of cancers, in addition to the viral diseases extensively reported by the Company to date.

Genethon, a unique non-profit gene therapy R&D organization founded by the French Muscular Dystrophy Association, provided an update on its efforts to employ Artificial Intelligence in revolutionizing the development and bioproduction of gene therapies.

Seneca Therapeutics, Inc., announced today Dr. Paul Hallenbeck will present a talk titled “ Facilitating multiple deliveries of therapeutic viruses by exploiting natural methods of evading neutralizing immunity ”, during the World Vaccine Congress in Santa Clara, CA on November 28, 2023.

An exclusive initiative by the Israeli biotechnology company Amorphical brings a breakthrough approach to treating a variety of chronic inflammatory and oncological diseases.

TFF Pharmaceuticals, Inc. today announced that company management will be participating in the 2023 Benchmark Discovery One-on-One Investor Conference being held December 7, 2023 at the New York Athletic Club in New York City.